Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
Conditions: Advanced Lung Carcinoma; Advanced Malignant Solid Neoplasm; Malignant Adrenal Gland Neoplasm; Metastatic Liver Carcinoma; Metastatic Lung Carcinoma; Metastatic Malignant Solid Neoplasm; Stage III Liver Cancer; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Liver Cancer; Stage IV Lung Cancer AJCC v8; Stage IVA Liver Cancer; Stage IVA Lung Cancer AJCC v8; Stage IVB Liver Cancer; Stage IVB Lung Cancer AJCC v8
Interventions: Biological: Anti-CTLA4 Monoclonal Antibody BMS-986218; Biological: Nivolumab; Radiation: Stereotactic Body Radiation Therapy
Sponsor: M.D. Anderson Cancer Center
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.